Display options
Cite
Farzadfard E, Kalantari T, Tamaddon G. Serum Expression of Seven MicroRNAs in Chronic Lymphocytic Leukemia Patients. J Blood Med. 2020;11:97-102doi: 10.2147/JBM.S230842.
Farzadfard, E., Kalantari, T., & Tamaddon, G. (2020). Serum Expression of Seven MicroRNAs in Chronic Lymphocytic Leukemia Patients. Journal of blood medicine, 1197-102. https://doi.org/10.2147/JBM.S230842
Farzadfard, Ehsan, et al. "Serum Expression of Seven MicroRNAs in Chronic Lymphocytic Leukemia Patients." Journal of blood medicine vol. 11 (2020): 97-102. doi: https://doi.org/10.2147/JBM.S230842
Farzadfard E, Kalantari T, Tamaddon G. Serum Expression of Seven MicroRNAs in Chronic Lymphocytic Leukemia Patients. J Blood Med. 2020 Mar 12;11:97-102. doi: 10.2147/JBM.S230842. eCollection 2020. PMID: 32210655; PMCID: PMC7075349.
Copy Download .nbib Format: NLM
Share it on

J Blood Med. 2020 Mar 12;11:97-102. doi: 10.2147/JBM.S230842. eCollection 2020.

Serum Expression of Seven MicroRNAs in Chronic Lymphocytic Leukemia Patients.

Journal of blood medicine

Ehsan Farzadfard, Tahereh Kalantari, Gholamhossein Tamaddon

Affiliations

  1. School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
  2. Department of Medical Biotechnology, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
  3. Department of Clinical Laboratory Sciences, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.
  4. Diagnostic Laboratory Sciences and Technology Research Center, School of Paramedical Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.

PMID: 32210655 PMCID: PMC7075349 DOI: 10.2147/JBM.S230842

Abstract

PURPOSE: MicroRNAs are small single-strand noncoding RNAs that can be deregulated in a variety of cancers. Over the past few years, multiple markers have been discovered in chronic lymphocytic leukemia (CLL). Among these, miRNAs seem to have important roles in the pathogenesis of CLL. The development and validation of miRNA-expression patterns as biomarkers should have a significant impact in cancer diagnosis, therapeutic success, and increasing the life expectancy of patients. In this study, to specify the utility of circulatory miRNA expression as noninvasive and useful biomarkers for CLL, we analyzed the dysregulation of seven miRNAs: miR30d, miR25-3p, miR19a-3p, miR133b, miR451a, miR145, and miR144 in CLL-patient sera.

METHODS: Thirty untreated patients with flow-cytometry confirmation of CLL were chosen. Serum samples were collected from 30 newly diagnosed CLL patients. Fifteen healthy samples were taken for comparison as controls. RNA was extracted using Trizol. RNA from CLL patient specimens was compared to controls with real-time PCR.

RESULTS: Seven miRNAs were differently expressed between CLL and normal specimens using the comparative 2

CONCLUSION: Real-time PCR is an applied means to perform high-throughput investigation of serum-RNA samples. We assessed the expression of seven miRNAs in CLL patients by this method. The results demonstrated that the use of miRNA-expression profiling may have an impressive role in the diagnosis of CLL. In addition, miRNA 19a-3p and 25-3p are known oncogenes with therapeutic and potential biomarkers.

© 2020 Farzadfard et al.

Keywords: chronic lymphocytic leukemia; circulatory microRNAs; noncoding RNA; real-time PCR

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

  1. Oncotarget. 2017 Jul 11;8(28):45060-45071 - PubMed
  2. Blood. 2006 Jan 15;107(2):742-51 - PubMed
  3. Adv Hematol. 2011;2011:347137 - PubMed
  4. Tumour Biol. 2017 Jun;39(6):1010428317703984 - PubMed
  5. J Clin Oncol. 2006 Jan 20;24(3):437-43 - PubMed
  6. Oncologist. 2006 Jan;11(1):21-30 - PubMed
  7. Nat Rev Cancer. 2010 Jan;10(1):37-50 - PubMed
  8. J Hematol Oncol. 2015 Feb 20;8:12 - PubMed
  9. Cell. 2004 Jan 23;116(2):281-97 - PubMed
  10. Blood. 2002 Jun 1;99(11):4087-93 - PubMed
  11. PLoS One. 2015 Jul 13;10(7):e0132403 - PubMed
  12. Br J Haematol. 2016 Jan;172(1):48-55 - PubMed
  13. Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004 - PubMed
  14. Oncotarget. 2017 May 16;8(20):33375-33392 - PubMed
  15. Oncotarget. 2012 Feb;3(2):195-202 - PubMed
  16. Oncotarget. 2014 Jan 30;5(2):309-25 - PubMed
  17. N Engl J Med. 1990 Sep 13;323(11):720-4 - PubMed
  18. Ann Hematol. 2017 Jan;96(1):33-50 - PubMed
  19. Nature. 2005 Jun 9;435(7043):828-33 - PubMed
  20. Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15535-40 - PubMed
  21. J Clin Oncol. 2007 Mar 1;25(7):799-804 - PubMed
  22. Clin Lymphoma Myeloma Leuk. 2016 Nov;16(11):593-606 - PubMed
  23. Blood. 2003 Jun 15;101(12):4944-51 - PubMed
  24. Blood. 2002 Aug 15;100(4):1410-6 - PubMed
  25. Arthritis Rheum. 2008 May;58(5):1284-92 - PubMed
  26. Nature. 2011 Jan 20;469(7330):336-42 - PubMed
  27. Cell. 2009 Jan 23;136(2):215-33 - PubMed
  28. Cancer Res. 2005 Nov 1;65(21):9628-32 - PubMed
  29. Genes Dev. 2009 Dec 15;23(24):2839-49 - PubMed
  30. Saudi Med J. 2019 Apr;40(4):317-327 - PubMed
  31. Asian Pac J Cancer Prev. 2014;15(8):3767-72 - PubMed
  32. Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 - PubMed
  33. Cancer Lett. 2011 Oct 1;309(1):62-70 - PubMed
  34. Biochem Pharmacol. 2016 Aug 1;113:88-96 - PubMed
  35. Dev Biol. 2007 Oct 15;310(2):442-53 - PubMed
  36. Int J Clin Exp Pathol. 2015 Aug 01;8(8):9147-53 - PubMed
  37. Annu Rev Med. 2009;60:167-79 - PubMed
  38. J Exp Clin Cancer Res. 2014 Aug 10;33:67 - PubMed
  39. J Exp Med. 2011 Apr 11;208(4):663-75 - PubMed
  40. Nature. 2007 Jun 28;447(7148):1130-4 - PubMed
  41. Semin Cancer Biol. 2003 Aug;13(4):253-8 - PubMed
  42. Eur J Cancer Care (Engl). 2004 Jul;13(3):279-87 - PubMed

Publication Types